Atlas Brown Inc. Has $441,000 Stock Position in Novo Nordisk A/S (NYSE:NVO)

Atlas Brown Inc. raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 33.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,130 shares of the company’s stock after buying an additional 1,285 shares during the period. Atlas Brown Inc.’s holdings in Novo Nordisk A/S were worth $441,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the business. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S in the 2nd quarter valued at $25,000. Abound Wealth Management raised its position in shares of Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after purchasing an additional 157 shares during the period. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $28,000. Capital Performance Advisors LLP bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth about $42,000. Finally, Carolina Wealth Advisors LLC acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $48,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on NVO shares. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Price Performance

NVO traded up $0.57 on Friday, hitting $86.21. 5,773,708 shares of the stock were exchanged, compared to its average volume of 7,152,096. The firm has a market capitalization of $386.87 billion, a price-to-earnings ratio of 27.90, a PEG ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 12 month low of $81.50 and a 12 month high of $148.15. The business has a 50-day moving average of $100.86 and a two-hundred day moving average of $119.79.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.